You can buy or sell Senseonics and other stocks, options, ETFs, and crypto commission-free!
Senseonics Holdings, Inc. engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a gluscose monitoring device which includes sensor, smart transmitter, and mobile application. Read More The company was founded on June 26, 2014 and is headquartered in Germantown, MD.
52 Week High
52 Week Low
Yahoo FinanceMar 25
Senseonics Unveils Eversense Bridge Program in the U.S.
Senseonics Holdings, Inc. SENS recently announced the commercial launch of the Eversense Bridge Patient Access Program in the United States. This program will enable diabetic patients access the company’s newly-approved Eversense continuous glucose monitoring (CGM) system, for $99, in addition to the cost of sensor placement. The program is in sync with Senseonics’ strategy to offer advanced and affordable medical care to diabetic patients. Senseonics is a global medical technology company specializing in...
Seeking AlphaMar 22
Senseonics launches the Eversense access program in U.S.
Senseonics Holdings (NYSEMKT:SENS) has launched the Eversense Bridge Program in U.S. Under the program, patients can access the Eversense continuous glucose monitoring (CGM) System, the only long-term CGM that lasts up to 90 days, for only $99* plus the cost of the sensor placement by the healthcare provider....
-$0.14 per share
-$0.04 per share